Basel Medical Regains Nasdaq Compliance After Ten Consecutive $1 Closing Days
BMGL•Basel Medical Group regained Nasdaq compliance after its ordinary shares met the minimum bid requirement for ten consecutive business days from June 23 to July 7, 2026. The company’s shares initially fell below the $1.00 threshold on January 22, 2026, triggering a deficiency notice and potential delisting risk.
1. Nasdaq Deficiency Notification
On January 22, 2026, Nasdaq informed Basel Medical Group that its ordinary shares had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days, resulting in a non-compliance notice under Listing Rule 5550(a)(2).
2. Regaining Compliance
Between June 23 and July 7, 2026, the closing bid price of the company’s shares remained at or above $1.00 for ten consecutive business days, satisfying the minimum bid price requirement and restoring compliance.
3. Listing Stability Restored
With compliance regained, Basel Medical Group avoids potential delisting, secures its continued Nasdaq listing, and reduces regulatory uncertainty for shareholders.
